KR102176463B1 - 디아실글리세롤 아실트랜스퍼라제 억제제로서의 신규 화합물 - Google Patents
디아실글리세롤 아실트랜스퍼라제 억제제로서의 신규 화합물 Download PDFInfo
- Publication number
- KR102176463B1 KR102176463B1 KR1020157016270A KR20157016270A KR102176463B1 KR 102176463 B1 KR102176463 B1 KR 102176463B1 KR 1020157016270 A KR1020157016270 A KR 1020157016270A KR 20157016270 A KR20157016270 A KR 20157016270A KR 102176463 B1 KR102176463 B1 KR 102176463B1
- Authority
- KR
- South Korea
- Prior art keywords
- dihydropyrimido
- amino
- indol
- mmol
- oxazepin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 O=*(c(c(Cl)ncn1)c1Cl)Cl Chemical compound O=*(c(c(Cl)ncn1)c1Cl)Cl 0.000 description 8
- VXWVFZFZYXOBTA-UHFFFAOYSA-N Brc1ccc2[nH]ccc2c1 Chemical compound Brc1ccc2[nH]ccc2c1 VXWVFZFZYXOBTA-UHFFFAOYSA-N 0.000 description 1
- VOMQXRZKBDMHLC-UHFFFAOYSA-N CC(NNC([n](ccc1c2)c1ccc2Br)=O)=O Chemical compound CC(NNC([n](ccc1c2)c1ccc2Br)=O)=O VOMQXRZKBDMHLC-UHFFFAOYSA-N 0.000 description 1
- PXWKNDLTUVZFCF-UHFFFAOYSA-N Cc(nc1)ccc1-[n](cc1)c(c(C2CC2)c2)c1cc2N Chemical compound Cc(nc1)ccc1-[n](cc1)c(c(C2CC2)c2)c1cc2N PXWKNDLTUVZFCF-UHFFFAOYSA-N 0.000 description 1
- YWOGOMGMPJORQZ-UHFFFAOYSA-N Cc1nnc(-[n](ccc2c3)c2ccc3Br)[o]1 Chemical compound Cc1nnc(-[n](ccc2c3)c2ccc3Br)[o]1 YWOGOMGMPJORQZ-UHFFFAOYSA-N 0.000 description 1
- AAJPUKMQNZADDA-UHFFFAOYSA-N Cc1nnc(-[n](ccc2c3)c2ccc3N(CCO)C(c(c(Cl)ccc2)c2Cl)=O)[o]1 Chemical compound Cc1nnc(-[n](ccc2c3)c2ccc3N(CCO)C(c(c(Cl)ccc2)c2Cl)=O)[o]1 AAJPUKMQNZADDA-UHFFFAOYSA-N 0.000 description 1
- CGZXVICFKVYGHJ-UHFFFAOYSA-N Cc1nnc(-[n](ccc2c3)c2ccc3N(CCOc2c3c(Cl)ncn2)C3=O)[o]1 Chemical compound Cc1nnc(-[n](ccc2c3)c2ccc3N(CCOc2c3c(Cl)ncn2)C3=O)[o]1 CGZXVICFKVYGHJ-UHFFFAOYSA-N 0.000 description 1
- YETPLQSPXWCBCK-UHFFFAOYSA-N Nc1cc(C2CC2)c2[nH]ccc2c1 Chemical compound Nc1cc(C2CC2)c2[nH]ccc2c1 YETPLQSPXWCBCK-UHFFFAOYSA-N 0.000 description 1
- RCKGOKZMPYWGPI-UHFFFAOYSA-N O=C(c(c(OCC1)ncn2)c2Cl)N1c(cc1cc2)ccc1[n]2-c1cccc(OC(F)(F)F)c1 Chemical compound O=C(c(c(OCC1)ncn2)c2Cl)N1c(cc1cc2)ccc1[n]2-c1cccc(OC(F)(F)F)c1 RCKGOKZMPYWGPI-UHFFFAOYSA-N 0.000 description 1
- CGCRGGOIWFJUGQ-UHFFFAOYSA-N OCCN(C(c(c(Cl)ncn1)c1Cl)=O)c(cc1cc2)ccc1[n]2-c1ccccc1OCc1ccccc1 Chemical compound OCCN(C(c(c(Cl)ncn1)c1Cl)=O)c(cc1cc2)ccc1[n]2-c1ccccc1OCc1ccccc1 CGCRGGOIWFJUGQ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Child & Adolescent Psychology (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Epidemiology (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN3593DE2012 | 2012-11-23 | ||
| IN3593/DEL/2012 | 2012-11-23 | ||
| IN750/DEL/2013 | 2013-03-14 | ||
| IN750DE2013 | 2013-03-14 | ||
| IN3172/DEL/2013 | 2013-10-25 | ||
| IN3172DE2013 | 2013-10-25 | ||
| PCT/US2013/071376 WO2014081994A1 (en) | 2012-11-23 | 2013-11-22 | Novel compounds as diacylglycerol acyltransferase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20150087852A KR20150087852A (ko) | 2015-07-30 |
| KR102176463B1 true KR102176463B1 (ko) | 2020-11-09 |
Family
ID=50776577
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020157016270A Expired - Fee Related KR102176463B1 (ko) | 2012-11-23 | 2013-11-22 | 디아실글리세롤 아실트랜스퍼라제 억제제로서의 신규 화합물 |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US20150322082A1 (https=) |
| EP (2) | EP2922551B1 (https=) |
| JP (1) | JP6279600B2 (https=) |
| KR (1) | KR102176463B1 (https=) |
| CN (1) | CN104918620B (https=) |
| AU (1) | AU2013347843B2 (https=) |
| BR (1) | BR112015011982A8 (https=) |
| CA (1) | CA2892304C (https=) |
| CL (1) | CL2015001397A1 (https=) |
| CY (1) | CY1121426T1 (https=) |
| DK (1) | DK2922551T3 (https=) |
| EA (1) | EA031114B1 (https=) |
| ES (1) | ES2708626T3 (https=) |
| HR (1) | HRP20190099T1 (https=) |
| HU (1) | HUE042483T2 (https=) |
| IL (1) | IL238835B (https=) |
| LT (1) | LT2922551T (https=) |
| ME (1) | ME03315B (https=) |
| MX (1) | MX363484B (https=) |
| NZ (1) | NZ630436A (https=) |
| PE (1) | PE20150967A1 (https=) |
| PH (1) | PH12015501109B1 (https=) |
| PL (1) | PL2922551T3 (https=) |
| PT (1) | PT2922551T (https=) |
| RS (1) | RS58539B1 (https=) |
| SG (1) | SG11201503761WA (https=) |
| SI (1) | SI2922551T1 (https=) |
| SM (1) | SMT201900230T1 (https=) |
| UA (1) | UA115079C2 (https=) |
| WO (1) | WO2014081994A1 (https=) |
| ZA (1) | ZA201503304B (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018052818A (ja) * | 2015-01-28 | 2018-04-05 | 武田薬品工業株式会社 | スルホンアミド化合物 |
| WO2018093698A1 (en) | 2016-11-18 | 2018-05-24 | Merck Sharp & Dohme Corp. | Indole derivatives useful as inhibitors of diacylglyceride o-acyltransferase 2 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090036425A1 (en) | 2007-08-02 | 2009-02-05 | Pfizer Inc | Substituted bicyclolactam compounds |
| US20100204119A1 (en) | 2009-02-02 | 2010-08-12 | Pfizer Inc | 4-amino-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-6(5h)-yl phenyl derivatives |
| WO2011121350A1 (en) | 2010-04-01 | 2011-10-06 | Astrazeneca Ab | 4 -amino -7,8- dihydropyrimido [5, 4 - f] [1, 4] oxazepin- 5 ( 6h) - one based dgat1 inhibitors |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100795462B1 (ko) * | 2006-09-27 | 2008-01-16 | 한국생명공학연구원 | 인돌 유도체, 이의 제조방법 및 이를 유효성분으로함유하는 대사성 질환 예방 및 치료용 약학적 조성물 |
| US20090076275A1 (en) * | 2007-09-19 | 2009-03-19 | David Robert Bolin | Diacylglycerol acyltransferase inhibitors |
| AR066169A1 (es) * | 2007-09-28 | 2009-07-29 | Novartis Ag | Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat |
| US8324385B2 (en) * | 2008-10-30 | 2012-12-04 | Madrigal Pharmaceuticals, Inc. | Diacylglycerol acyltransferase inhibitors |
| PT2710013T (pt) * | 2011-05-20 | 2016-09-28 | Glaxosmithkline Intellectual Property (No 2) Ltd | Compostos novos como inibidores de diacilglicerol aciltransferas |
-
2013
- 2013-11-22 BR BR112015011982A patent/BR112015011982A8/pt active Search and Examination
- 2013-11-22 PT PT13856479T patent/PT2922551T/pt unknown
- 2013-11-22 AU AU2013347843A patent/AU2013347843B2/en not_active Ceased
- 2013-11-22 UA UAA201506216A patent/UA115079C2/uk unknown
- 2013-11-22 PL PL13856479T patent/PL2922551T3/pl unknown
- 2013-11-22 CN CN201380069807.4A patent/CN104918620B/zh not_active Expired - Fee Related
- 2013-11-22 ES ES13856479T patent/ES2708626T3/es active Active
- 2013-11-22 ME MEP-2019-14A patent/ME03315B/me unknown
- 2013-11-22 LT LTEP13856479.4T patent/LT2922551T/lt unknown
- 2013-11-22 MX MX2015006533A patent/MX363484B/es unknown
- 2013-11-22 SI SI201331321T patent/SI2922551T1/sl unknown
- 2013-11-22 HR HRP20190099TT patent/HRP20190099T1/hr unknown
- 2013-11-22 EP EP13856479.4A patent/EP2922551B1/en active Active
- 2013-11-22 EP EP18203369.6A patent/EP3492474B1/en active Active
- 2013-11-22 WO PCT/US2013/071376 patent/WO2014081994A1/en not_active Ceased
- 2013-11-22 US US14/646,403 patent/US20150322082A1/en not_active Abandoned
- 2013-11-22 KR KR1020157016270A patent/KR102176463B1/ko not_active Expired - Fee Related
- 2013-11-22 SG SG11201503761WA patent/SG11201503761WA/en unknown
- 2013-11-22 SM SM20190230T patent/SMT201900230T1/it unknown
- 2013-11-22 JP JP2015544141A patent/JP6279600B2/ja not_active Expired - Fee Related
- 2013-11-22 HU HUE13856479A patent/HUE042483T2/hu unknown
- 2013-11-22 DK DK13856479.4T patent/DK2922551T3/en active
- 2013-11-22 RS RS20190081A patent/RS58539B1/sr unknown
- 2013-11-22 EA EA201590982A patent/EA031114B1/ru unknown
- 2013-11-22 CA CA2892304A patent/CA2892304C/en not_active Expired - Fee Related
- 2013-11-22 PE PE2015000657A patent/PE20150967A1/es unknown
- 2013-11-22 NZ NZ630436A patent/NZ630436A/en not_active IP Right Cessation
-
2015
- 2015-05-12 ZA ZA2015/03304A patent/ZA201503304B/en unknown
- 2015-05-14 IL IL238835A patent/IL238835B/en active IP Right Grant
- 2015-05-19 PH PH12015501109A patent/PH12015501109B1/en unknown
- 2015-05-22 CL CL2015001397A patent/CL2015001397A1/es unknown
-
2019
- 2019-01-29 CY CY20191100120T patent/CY1121426T1/el unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090036425A1 (en) | 2007-08-02 | 2009-02-05 | Pfizer Inc | Substituted bicyclolactam compounds |
| US20100204119A1 (en) | 2009-02-02 | 2010-08-12 | Pfizer Inc | 4-amino-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-6(5h)-yl phenyl derivatives |
| WO2011121350A1 (en) | 2010-04-01 | 2011-10-06 | Astrazeneca Ab | 4 -amino -7,8- dihydropyrimido [5, 4 - f] [1, 4] oxazepin- 5 ( 6h) - one based dgat1 inhibitors |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI853806B (zh) | 小分子pd-1/pd-l1抑制劑、其與pd-l1抗體的藥物組合物及其應用 | |
| JP5844456B2 (ja) | ジアシルグリセロールアシルトランスフェラーゼ阻害剤としての新規化合物 | |
| US9879031B2 (en) | Compounds as diacylglycerol acyltransferase inhibitors | |
| JP2024508235A (ja) | 三環－アミド－二環ｐｒｍｔ５阻害剤 | |
| EP2909193B1 (en) | Phenyl linked quinolinyl modulators of ror-gamma-t | |
| KR101816942B1 (ko) | 키누레닌 생성 억제 작용을 갖는 함질소 복소환 화합물 | |
| EP2435048B1 (en) | Radiolabeled pde10 inhibitors | |
| TW201418254A (zh) | 作為ｃ－Ｍｅｔ酪氨酸激酶抑制劑的新型稠合吡啶衍生物 | |
| KR102176463B1 (ko) | 디아실글리세롤 아실트랜스퍼라제 억제제로서의 신규 화합물 | |
| WO2022194265A1 (zh) | 一种喹唑啉类化合物、组合物及其应用 | |
| JP2022551180A (ja) | イソクエン酸デヒドロゲナーゼ（ｉｄｈ）阻害剤 | |
| TW202539664A (zh) | 具有血清素受體結合活性之含氮芳香族雜環及芳香族碳環衍生物 | |
| HK1214757B (en) | Novel compounds as diacylglycerol acyltransferase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| P22-X000 | Classification modified |
St.27 status event code: A-2-2-P10-P22-nap-X000 |
|
| A201 | Request for examination | ||
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |
|
| R17-X000 | Change to representative recorded |
St.27 status event code: A-3-3-R10-R17-oth-X000 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| R17-X000 | Change to representative recorded |
St.27 status event code: A-3-3-R10-R17-oth-X000 |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
St.27 status event code: A-1-2-D10-D22-exm-PE0701 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U12-oth-PR1002 Fee payment year number: 1 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |
|
| R17-X000 | Change to representative recorded |
St.27 status event code: A-5-5-R10-R17-oth-X000 |
|
| PC1903 | Unpaid annual fee |
St.27 status event code: A-4-4-U10-U13-oth-PC1903 Not in force date: 20231104 Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE |
|
| PC1903 | Unpaid annual fee |
St.27 status event code: N-4-6-H10-H13-oth-PC1903 Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE Not in force date: 20231104 |